AEF vs AUTL Comparison

ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a non-diversified closed-end, management investment company. Its investment objective is to seek to provide both current income and long-term capital appreciation. Under normal circumstances, the fund invests a majority of its net assets (plus any borrowings for investment purposes) in emerging markets (excluding China) equity securities. The performance of the fund is measured against the MSCI Emerging Markets ex-China Index. Its investment portfolio consists of equity securities from emerging market companies (excluding China), spanning multiple sectors such as Information Technology, Financials, Industrials, Consumer Discretionary, Real Estate, and others.

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.